Low-dose quetiapine,
does it really help with Improved sleep onset and maintenance in primary insomnia?
research showsLow-dose quetiapine is rated F for primary insomnia. The only direct double-blind randomized trial used 25 mg for two weeks and had only 13 completers; total sleep time, sleep latency, and sleep satisfaction were all statistically nonsignificant versus placebo. A systematic review found no other eligible trial, while the 2023 European insomnia guideline and 2025 VA/DoD guideline recommend against antipsychotics because efficacy evidence is lacking and harms are possible. Causing drowsiness does not establish effective primary-insomnia therapy or safe long-term use.
ads claimPrescribing custom and strong drowsiness can be packaged as a nonaddictive sleep aid, safety at low dose, and all-night maintenance. Antipsychotic sedation is not established efficacy for primary insomnia, and low doses do not remove metabolic or cardiac harm.
Useful facts when choosing a product
- Quetiapine is an atypical antipsychotic approved for conditions such as schizophrenia and bipolar disorder. Treatment of primary insomnia alone is off-label, and the 25-to-100-mg doses commonly used for sleep are not approved hypnotic doses.
- The only placebo-controlled trial in primary insomnia used 25 mg for two weeks and had 13 completers. A small null trial cannot establish individual benefit or durable long-term efficacy.
- Weight gain, increased appetite, worsening glucose and lipids, and daytime sedation can occur even at low doses. Long-term use requires monitoring of weight, waist, blood pressure, glucose, and lipids.
- Orthostatic hypotension, falls, QT prolongation, and rare movement disorders or neuroleptic malignant syndrome can occur, while alcohol and other sedatives increase impairment. It should not be started independently or stopped abruptly without discussing it with the prescriber.
What the research actually shows
The direct trial gave 25 mg or placebo for two weeks to patients with DSM-IV-TR primary insomnia; only 13 completed it and all subjective sleep-diary outcomes were nonsignificant. The 2016 systematic review found no other eligible antipsychotic trial. The 2023 European insomnia guideline concluded that scientific evidence does not support antipsychotics including quetiapine for insomnia without comorbidity. The 2025 VA/DoD guideline likewise recommended against use because efficacy evidence is lacking and metabolic, cardiovascular, and neurologic harms can occur even at low doses.
Why this is classified as F (8)
The only direct primary-insomnia trial lasted two weeks, had 13 completers, and found no significant placebo difference; systematic review and European and VA/DoD guidelines recommend against use because efficacy is lacking and harm is possible. The null-trial and guideline-opposition rule gives F with 8 points. Metabolic, cardiac, and daytime-sedation risks remain separate safety concerns.
Counterpoint. Persistent insomnia calls for CBT-I first and assessment of sleep apnea, depression or anxiety, pain, medicines, caffeine, restless legs, and other causes. If medication is needed, options with an insomnia indication and supporting evidence should be compared with a clinician.
Rejudgment record. New verdict — Applied the repeated-refutation and guideline-opposition rule because the sole direct primary-insomnia trial was nonsignificant in 13 completers, systematic review found no additional evidence, and European and VA/DoD guidelines recommend against antipsychotics for insomnia due to insufficient efficacy and harms
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved sleep onset and maintenance in primary insomnia | F | The only 13-person trial was nonsignificant, and guidelines recommend against use because efficacy is lacking and harms are possible. |
| Metabolic and cardiac safety of low-dose off-label use | F | Low doses do not eliminate weight, glucose, lipid, orthostatic, QT, or daytime-sedation risks. |
| Treatment identical to verdict 583 diphenhydramine | F | Like verdict 583 it is an F insomnia precedent, but the ingredient and mechanism differ; quetiapine is also an off-label antipsychotic distinct from zolpidem and orexin antagonists. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Randomized double-blind placebo-controlled trial | 13 | Academic single-center study; detailed funding not disclosed | Two-week sleep-diary total sleep time, sleep latency, daytime function, and sleep satisfaction | Quetiapine 25 mg showed only trends toward improvement, with no statistically significant placebo comparison. | Only direct randomized trial; null result |
| Study 2 | Systematic review of atypical antipsychotics for insomnia | 13 | Canadian academic investigators | Total sleep time, sleep latency, and sleep satisfaction | Confidence intervals for all effects included no effect, and no additional direct evidence was found. | Key confirmation of null evidence and evidence gap |
| Study 3 | Systematic evidence review and clinical guideline | European Sleep Research Society | Short- and long-term insomnia efficacy and harms | Antipsychotics including quetiapine were not recommended for insomnia without comorbidity. | Key guideline recommendation against use | |
| Study 4 | Evidence-based clinical practice guideline | United States Departments of Veterans Affairs and Defense | Chronic-insomnia efficacy and safety | It issued a weak recommendation against antipsychotics because efficacy evidence was lacking and harms were possible. | Current guideline recommendation against use |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-19).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-19 · Corrections: none
Cite this verdict
[Chamgap] Low-dose quetiapine x improved sleep onset and maintenance in primary insomnia — Evidence Grade F·8. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/sleep/low-dose-quetiapine-primary-insomnia-sleep-onset-maintenance/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.